INDV Insider Trading

Insider Ownership Percentage: 3.44%
Insider Buying (Last 12 Months): £14,989.40
Insider Selling (Last 12 Months): £424,476.69

Indivior Insider Trading History Chart

This chart shows the insider buying and selling history at Indivior by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
20222023202420250bought0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-40M-20M020M40MTotal Insider BuyingTotal Insider Selling

Indivior Share Price & Price History

Current Price: GBX 975
Price Change: Price Decrease of -17 (-1.71%)
As of 01/22/2025 11:47 AM ET

This chart shows the closing price history over time for INDV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan996.37Closing price on 01/21/25:

Indivior Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Indivior (LON:INDV)

85.98% of Indivior stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Indivior logo
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More on Indivior

Today's Range

Now: GBX 975
Low: 964.50
High: 1,011

50 Day Range

MA: GBX 910.87
Low: 769
High: 1,024

52 Week Range

Now: GBX 975
Low: 554.50
High: 1,770

Volume

67,447 shs

Average Volume

1,240,801 shs

Market Capitalization

£1.25 billion

P/E Ratio

N/A

Dividend Yield

4.48%

Beta

0.19

Who are the company insiders with the largest holdings of Indivior?

Indivior's top insider shareholders include:
  1. Graham Hetherington (Insider)
  2. Jo Le Couilliard (Insider)
  3. Mark Crossley (Insider)
  4. Mark Stejbach (Insider)
Learn More about top insider investors at Indivior.